Unfortunately, this often ends up failing, and the INTUITT-NF2 trial (Innovative Trial for Understanding the Impact of Targeted Therapies in NF2, NCT04374305) under the umbrella of the Children’s Tumor Foundation and Takeda Pharmaceuticals led by Scott Plotkin (Massachusetts General Hospital) and Jaishri Blakely (Johns Hopkins University) is underway to look at patients with vestibular schwannomas, ependymomas, and meningiomas in the NF2 population. This evidence concerns the gene NF2 and ependymoma.